Literature DB >> 28572272

A novel prion protein variant in a patient with semantic dementia.

Joanna Kenny1,2, Ione Woollacott3, Carolin Koriath3, Laszlo Hosszu1, Gary Adamson1, Peter Rudge2, Martin N Rossor3, John Collinge1,2, Jonathan D Rohrer3, Simon Mead1,2.   

Abstract

Entities:  

Keywords:  CREUTZFELDT-JAKOB DISEASE; DEMENTIA; NEUROGENETICS; PRION; SEMANTIC DEMENTIA

Mesh:

Substances:

Year:  2017        PMID: 28572272      PMCID: PMC5629930          DOI: 10.1136/jnnp-2017-315577

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


× No keyword cloud information.
Prion diseases are a group of fatal neurodegenerative diseases that can be sporadic, inherited or acquired. Inherited prion diseases are caused by mutations in the prion protein gene, PRNP, usually single nucleotide substitutions or structural variants of an octapeptide repeat encoding region. Although the classical presentation of sporadic Creutzfeldt Jakob disease (CJD) is rapidly progressive ataxia, myoclonus and cognitive decline, the presentation of genetic cases is variable and decline can be much slower. Prion diseases can mimic many neurodegenerative diseases. Genetic dementias are pleiotropic, with similar clinical syndromes being caused by mutations in different genes; additionally, mutations in a single gene may cause diverse clinical phenotypes. Due to the diagnostic difficulties arising from this clinical and genetic heterogeneity, next-generation sequencing technologies including gene panels and exome sequencing are helpful in elucidating genetic causes of dementia.1 Here we report a novel variant in PRNP in a patient diagnosed with semantic dementia, a variant of frontotemporal dementia (FTD). Patients with semantic dementia develop progressive loss of semantic knowledge resulting in significant early language impairment, with subsequent wider cognitive impairment and behavioural problems. MRI appearances are characteristic with focal asymmetric anteroinferior temporal lobe atrophy. The predominant histopathological finding is accumulation of Tar DNA-binding protein 43 (TDP-43) deposits in the temporal and frontal lobes, although other pathologies, including Alzheimer’s disease, are occasionally observed.2 A Mendelian genetic aetiology is rarely documented. A woman in her seventh decade presented with a 1-year history of rapidly progressive language problems and behavioural change. She had particular difficulty naming objects and suffered from impaired comprehension, but had preserved recognition of faces and episodic memory. Over the same time period her personality changed, becoming disinhibited and exhibiting obsessional behaviour. She also struggled with cooking but not with self-care or housework. She had no significant surgical or medical history, apart from a 5-year history of tinnitus and deafness, and took no regular medications. A family history of dementia was known: her mother developed dementia of uncertain aetiology in her seventh decade, which progressed steadily with a total duration of 10 years. Her father died in his eighth decade of a myocardial infarction. There was no other relevant family history. Physical examination revealed bilateral sensorineural hearing loss, globally brisk tendon reflexes, positive pout reflex and mild bilateral limb apraxia, but was otherwise unremarkable. She scored 23/30 on Mini-Mental State Examination (MMSE). On formal neuropsychometric testing, she obtained a verbal IQ of 66 and performance IQ of 78. Testing of specific cognitive domains revealed significantly impaired single word comprehension (Peabody Picture Vocabulary Test) and anomia (Oldfield Naming Test), as well as a surface dyslexia and dysgraphia, consistent with an impairment of verbal semantic knowledge. Other cognitive domains, including calculation, non-verbal reasoning (Raven’s Coloured Matrices), episodic memory (Camden Pictorial Recognition Memory Test) and visuospatial skills, were intact. Dementia screening bloods and cerebrospinal fluid analysis (undertaken prior to the availability of Aβ42 and tau measurements) were normal. An MRI scan was reported as showing scattered white matter lesions in both cerebral hemispheres, presumed secondary to mild small vessel disease, with evidence of generalised brain atrophy, although the scan was unavailable for review. A diagnosis of semantic dementia was made based on the history and pattern of her cognitive deficits. She was next reviewed 5 years later when she had deteriorated significantly with very limited comprehension and frequent use of jargon words, as well as presenting with visual agnosia. Her behaviour had deteriorated, becoming severely apathetic, losing interest in all of her previous hobbies, increasingly obsessive, particularly with time-keeping, markedly disinhibited, and developing a sweet tooth. She could no longer do housework and struggled with personal activities of daily living. The patient was subsequently lost to follow-up and died 10 years after onset without being examined at postmortem. Twenty years after presentation, a DNA sample was tested using the Medical Research Council (MRC) Dementia Gene Panel, a custom next-generation sequencing technology covering 17 dementia genes, including common FTD-associated genes such as MAPT and GRN.1 Samples were tested separately for C9orf72 expansions and PRNP octapeptide repeat insertions/deletions. Results were analysed for known and novel variants and confirmed by Sanger sequencing. We discovered a novel PRNP variant (R156C, g.4680332C>T), which is absent from 141 362 unrelated individuals’ exome and whole-genome sequences collated by the Exome Aggregation Consortium (http://gnomad.broadinstitute.org/). The patient was homozygous for methionine at codon 129 (129MM). No other pathogenic mutations or risk factors for neurodegeneration were identified. The variant results in the replacement of a large, positively charged arginine residue, located immediately after the first α-helix of the prion protein (PrPC), with a smaller polar, uncharged cysteine (figure 1). As this amino acid is located on the PrPC surface, it is unlikely to cause a gross conformational change in PrPC. However, cysteines may form intermolecular or intramolecular covalent disulphide bonds. Indeed, the two wild-type cysteines present in PrPC form a disulphide bond, which is essential to the fold stability of the protein.3 We hypothesise that the introduction of an additional cysteine might disrupt the normal PrPC disulphide bond or result in the formation of intermolecular disulphide bonds, as observed previously.4 A similar arginine to cysteine mutation, R208C, has been found in a single case with CJD.5 A few other mutations have been reported in the region between first and second α-helices including Q160X, Y163X, D167G and D167N, some of which follow a very atypical clinical course.6 No mutations have been reported at position 156, but in silico modelling (Polyphen, SIFT, FATHMM, MutationAssessor, MutationTaster) suggests that this variant is likely to be pathogenic. However, Minikel et al 7 demonstrated that the frequency of PRNP missense and truncating variants in the general population is incompatible with the incidence of prion diseases. Novel variants thus need to be assessed with caution regarding their pathogenicity in the absence of segregation or functional data despite their rarity.
Figure 1

Ribbon representation of the structure of the folded domain of the human prion protein,3 with α-helices coloured red, β-strands cyan and loops white. The mutated cysteine side chain of residue 156 is shown in yellow. The disulphide bond linking the side chains of the other cysteines in the protein (Residues 179 and 214) is shown in magenta. This figure was prepared using PyMOL (Schrödinger).

Ribbon representation of the structure of the folded domain of the human prion protein,3 with α-helices coloured red, β-strands cyan and loops white. The mutated cysteine side chain of residue 156 is shown in yellow. The disulphide bond linking the side chains of the other cysteines in the protein (Residues 179 and 214) is shown in magenta. This figure was prepared using PyMOL (Schrödinger). We report a novel missense mutation of PRNP in a patient with semantic dementia, which would at present be classified as likely pathogenic. Patients with semantic dementia would not normally be recommended for genetic studies, particularly of PRNP. The use of next-generation sequencing technologies will be increasingly important in elucidating the causes of pleiotropic conditions such as familial dementia.
  7 in total

1.  Crystal structure of the human prion protein reveals a mechanism for oligomerization.

Authors:  K J Knaus; M Morillas; W Swietnicki; M Malone; W K Surewicz; V C Yee
Journal:  Nat Struct Biol       Date:  2001-09

2.  PRNP mutations in a series of apparently sporadic neurodegenerative dementias in China.

Authors:  Liu Zheng; Jia Longfei; Ye Jing; Zhang Xinqing; Song Haiqing; Lv Haiyan; Wang Fen; Dong Xiumin; Jia Jianping
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-09-05       Impact factor: 3.568

Review 3.  Semantic dementia: a unique clinicopathological syndrome.

Authors:  John R Hodges; Karalyn Patterson
Journal:  Lancet Neurol       Date:  2007-11       Impact factor: 44.182

4.  Quantifying prion disease penetrance using large population control cohorts.

Authors:  Eric Vallabh Minikel; Sonia M Vallabh; Monkol Lek; Karol Estrada; Kaitlin E Samocha; J Fah Sathirapongsasuti; Cory Y McLean; Joyce Y Tung; Linda P C Yu; Pierluigi Gambetti; Janis Blevins; Shulin Zhang; Yvonne Cohen; Wei Chen; Masahito Yamada; Tsuyoshi Hamaguchi; Nobuo Sanjo; Hidehiro Mizusawa; Yosikazu Nakamura; Tetsuyuki Kitamoto; Steven J Collins; Alison Boyd; Robert G Will; Richard Knight; Claudia Ponto; Inga Zerr; Theo F J Kraus; Sabina Eigenbrod; Armin Giese; Miguel Calero; Jesús de Pedro-Cuesta; Stéphane Haïk; Jean-Louis Laplanche; Elodie Bouaziz-Amar; Jean-Philippe Brandel; Sabina Capellari; Piero Parchi; Anna Poleggi; Anna Ladogana; Anne H O'Donnell-Luria; Konrad J Karczewski; Jamie L Marshall; Michael Boehnke; Markku Laakso; Karen L Mohlke; Anna Kähler; Kimberly Chambert; Steven McCarroll; Patrick F Sullivan; Christina M Hultman; Shaun M Purcell; Pamela Sklar; Sven J van der Lee; Annemieke Rozemuller; Casper Jansen; Albert Hofman; Robert Kraaij; Jeroen G J van Rooij; M Arfan Ikram; André G Uitterlinden; Cornelia M van Duijn; Mark J Daly; Daniel G MacArthur
Journal:  Sci Transl Med       Date:  2016-01-20       Impact factor: 17.956

5.  Definable equilibrium states in the folding of human prion protein.

Authors:  Laszlo L P Hosszu; Mark A Wells; Graham S Jackson; Samantha Jones; Mark Batchelor; Anthony R Clarke; C Jeremy Craven; Jonathan P Waltho; John Collinge
Journal:  Biochemistry       Date:  2005-12-20       Impact factor: 3.162

6.  Validation of next-generation sequencing technologies in genetic diagnosis of dementia.

Authors:  John Beck; Alan Pittman; Gary Adamson; Tracy Campbell; Joanna Kenny; Henry Houlden; Jon D Rohrer; Rohan de Silva; Maryam Shoai; James Uphill; Mark Poulter; John Hardy; Catherine J Mummery; Jason D Warren; Jonathan M Schott; Nick C Fox; Martin N Rossor; John Collinge; Simon Mead
Journal:  Neurobiol Aging       Date:  2013-08-31       Impact factor: 4.673

7.  A novel prion disease associated with diarrhea and autonomic neuropathy.

Authors:  Simon Mead; Sonia Gandhi; Janice L Holton; John Collinge; Jon Beck; Diana Caine; Dillip Gallujipali; Christopher Carswell; Harpreet Hyare; Susan Joiner; Hilary Ayling; Tammaryn Lashley; Jacqueline M Linehan; Huda Al-Doujaily; Bernadette Sharps; Tamas Revesz; Malin K Sandberg; Mary M Reilly; Martin Koltzenburg; Alastair Forbes; Peter Rudge; Sebastian Brandner; Jason D Warren; Jonathan D F Wadsworth; Nicholas W Wood
Journal:  N Engl J Med       Date:  2013-11-14       Impact factor: 91.245

  7 in total
  1 in total

1.  Alterations of Striatal Subregions in a Prion Protein Gene V180I Mutation Carrier Presented as Frontotemporal Dementia With Parkinsonism.

Authors:  Zhongyun Chen; Jinghong Ma; Li Liu; Shuying Liu; Jing Zhang; Min Chu; Zhen Wang; Piu Chan; Liyong Wu
Journal:  Front Aging Neurosci       Date:  2022-04-15       Impact factor: 5.702

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.